OncoPharm

John Bossaer
undefined
Jan 19, 2018 • 18min

Landmarks in Oncology Pharmacy: MOPP

The Landmarks series continues with DeVita's original MOPP (Hodgkin's Disease) publication from 1970. Discussion points include WBC monitoring, why cyclophosphamide isn't included, and wigs.
undefined
12 snips
Jan 12, 2018 • 15min

Foundations in Oncology Pharmacy: Cisplatin

The Foundations in Oncology Pharmacy series begins with the penicillin of oncology: cisplatin. Discussion of its history, current uses, & toxicities. Perfect for those new to oncology pharmacy.
undefined
Jan 5, 2018 • 20min

Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)

Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.
undefined
Jan 1, 2018 • 14min

Landmarks in Oncology Pharmacy: Acute Leukemia in 1958

In the 1st of the Landmarks series, we look back at a pivotal article published in Blood in 1958 on the treatment of acute leukemia.
undefined
Dec 18, 2017 • 24min

2017 Was A Good Year

2017 saw A LOT of #oncopharm approvals. Oncology pharmacist & educator John Bossaer runs through some of the most notable oncology pharmacy trends of the year, include CAR-T cell therapy
undefined
Nov 30, 2017 • 17min

Tales of Brave Iressa

Discussion of gefitinib's journey back to the market and lessons to be learned from it by oncology pharmacist & educator John Bossaer.
undefined
Nov 17, 2017 • 19min

Adjuvant TKIs?

Recent FDA updates & a brief discussion about adjuvant TKI use in solid tumors.
undefined
Nov 1, 2017 • 13min

Acalabrutinib

Oncology Pharmacy Podcast discussing the FDA-approval of acalabrutinib

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app